OPKO Health’s BioReference Launches Direct-To-Consumer Diagnostic Platform
Event summary
- BioReference, an OPKO Health subsidiary, launched BioReference Direct™ on April 30, 2026, a digital platform for consumer-initiated diagnostic testing.
- The platform offers wellness panels, women’s and men’s health tests, and Abbott’s simpli-COLLECT™ STI Test via telehealth review.
- BioReference leverages its 45-year lab expertise and existing patient service centers in New York and New Jersey for the service.
The big picture
BioReference Direct reflects the broader shift toward consumer-driven healthcare, where diagnostics play a central role. The platform’s launch aligns with OPKO Health’s strategy to expand access to testing while leveraging its existing clinical infrastructure. Success will depend on scaling user adoption and maintaining regulatory compliance in an increasingly competitive market.
What we're watching
- Market Adoption
- Whether BioReference Direct can capture significant market share in the growing consumer-driven diagnostics space.
- Regulatory Compliance
- How the platform navigates telehealth and at-home testing regulations across different states.
- Competitive Positioning
- The pace at which BioReference can differentiate itself from competitors like LabCorp and Quest Diagnostics in direct-to-consumer diagnostics.
Related topics